Mustang Bio Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for difficult-to-treat cancers and autoimmune diseases. The company’s current programs center on CAR T cell therapies and related oncology platforms designed to target hematologic malignancies, solid tumors, and other serious conditions with high unmet medical need. Mustang Bio works to advance these therapies through research, licensing, and collaboration with medical institutions, positioning itself within the broader precision medicine and immunotherapy markets. Headquartered in Waltham, Massachusetts, Mustang Bio plays a specialized role in the biotechnology sector by translating scientific breakthroughs into potential therapeutic products for patients facing complex and often life-threatening diseases.
Website95 Sawyer Road
Waltham, MA, 02453
United States
Investors talking about MBIO also mention
What share of all stock conversation is about MBIO?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% new | 0% 0 |
Of the messages about MBIO that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 79.55% -1.69 | ||
| Bearish | — | — | — | 20.45% +1.69 |
Of the messages about MBIO that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 100% | 73.2% | ||
| Analysts | — | — | 0% | 0% | ||
| Controversies | — | — | 0% | 0% | ||
| Earnings | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 0% | ||
| Technical Analysis | — | — | 0% | 26.8% |
Of the messages about MBIO, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 25.51% | ||
| Newcomers | — | — | 100% | 74.49% |